Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Targeted patients

<< Previous

Bullboard Posts

Next >>

Post by canadapieton Aug 03, 2022 2:13pm

105 Views

Post# 34868867

Targeted patients

"This is Theratechnologies’ first-in-human study of TH1902, its investigational lead peptide drug conjugate (“PDC”) linked to docetaxel for the treatment of sortilin-expressing cancers."

So they clearly state a study for "sortilin-expressing cancers" ......., but there are no tools/procedures to measure that?????

OMG

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario